布洛芬固体脂质微颗粒的制备及其晶体构型研究

CIESC Journal

• PROCESS AND PRODUCT TECHNOLOGY • 上一篇下一篇

布洛芬固体脂质微颗粒的制备及其晶体构型研究

龙春霞; 章莉娟; 钱宇

School of Chemical & Energy Engineering, South China University of Technology, Guangzhou 510640, China

收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2006-08-28 发布日期:2006-08-28
通讯作者: 龙春霞

Preparation and Crystal Modification of Ibuprofen-Loaded Solid Lipid Microparticles

LONGChunxia; ZHANGLijuan; QIANYu

School of Chemical & Energy Engineering, South China University of Technology, Guangzhou 510640, China

Received:1900-01-01 Revised:1900-01-01 Online:2006-08-28 Published:2006-08-28
Contact: LONG Chunxia

摘要/Abstract

摘要： An emulsion-congealing technique is used to prepare solid lipid microparticles (SLM) containing ibuprofen with glyceryl behenate, tripalmitin and beewax as excipients. The difference of the solubility parameters between the excipients and ibuprofen are used to analyze their compatibility. Both the solubility parameter analysis and the experimental results show that glyceryl behenate is the best among the three excipients. The solid particles disperse well in aqueous phase when the drug loading reaches 10% (relative to lipid only). Glycerides exhibit marked polymorphism and their rapid rates of crystallization accelerate the formation of metastable crystal modification. The metastable crystal modification characterizes high drug loading capacity but less stability. Increasing the content of lipophilic drug in a lipid matrix facilitates the transformation of excipients to more stable polymorphic forms.

关键词: solid lipid microparticles;crystal modification;solubility parameter;drug loading capacity;ibuprofen

Abstract: An emulsion-congealing technique is used to prepare solid lipid microparticles (SLM) containing ibuprofen with glyceryl behenate, tripalmitin and beewax as excipients. The difference of the solubility parameters between the excipients and ibuprofen are used to analyze their compatibility. Both the solubility parameter analysis and the experimental results show that glyceryl behenate is the best among the three excipients. The solid particles disperse well in aqueous phase when the drug loading reaches 10% (relative to lipid only). Glycerides exhibit marked polymorphism and their rapid rates of crystallization accelerate the formation of metastable crystal modification. The metastable crystal modification characterizes high drug loading capacity but less stability. Increasing the content of lipophilic drug in a lipid matrix facilitates the transformation of excipients to more stable polymorphic forms.

Key words: solid lipid microparticles, crystal modification, solubility parameter, drug loading capacity, ibuprofen

龙春霞, 章莉娟, 钱宇. 布洛芬固体脂质微颗粒的制备及其晶体构型研究[J]. CIESC Journal.

LONGChunxia, ZHANGLijuan, QIANYu. Preparation and Crystal Modification of Ibuprofen-Loaded Solid Lipid Microparticles[J]. .

参考文献

1    Mehnert, W., Mäder, K., “Solid lipid nanoparticles pro-duction, characterization and applications”, Adv. Drug Deliv. Rev., 47, 165—196(2001).
2    Gasco, M.R., “Method for producing solid lipid micro-spheres having a marrow size distribution”, US Pat., 5250236 (1993).
3    Müller, R.H., Radtke, M., Wissing, S.A., “Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations”, Adv. Drug Deliv. Rev., 54(Suppl. 1), S131—S155(2002).
4    Hu, F.Q., Hong, Y., Yuan, H., “Preparation and charac-terization of solid lipid nanoparticles containing peptide”, Int. J. Pharm., 273, 29—35(2004).
5    Schwarz, C., Mehnert, W., Lucks, J.S., Müller, R.H., “Solid lipid nanoparticles (SLN) for controlled drug de-livery І. Production, characterisation and sterilization”, J. Control. Release, 30, 83—96(1994).
6    Lamprecht, A., Bouligand, Y., Benoit, J.P., “New lipid nanocapsules exhibit sustained release properties for amiodarone”, J. Control. Release, 84, 59—68(2002).
7    Venkateswarlu, V., Manjunath, K., “Preparation, char-acterization and in vitro release kinetics of clozapine solid lipid nanoparticles”, J. Control. Release, 95, 627—638(2004).
8    Mühlen, A.Z., Mühlen, E.Z., Niehus, H., Mehnert, W., “Atomic force microscopy studies of solid lipid nanopar-ticles”, Pharm. Res., 13(9), 1411—1416(1996).
9    Liu, J., Xiao, Y., Allen, C., “Polymer-drug compatibility: A guide to the development of delivery systems for the anticancer agent, ellipticine”, J. Pharm. Sci., 93(1),  132—143(2004).
10    Six, K., Verreck, G., Peeters, J., Brewster, M., Mooter, G.V.D., “Increased physical stability and improved dis-solution properties of itraconazole, a class Π drug, by solid dispersions that combine fast- and slow-dissolving polymers”, J. Pharm. Sci., 93 (1), 124—131(2004).
11    Domb, A.J., Baltimore, M., “Lipsopheres for controlled delivery of substances”, US Pat., 5188837 (1993).
12    Rowe, R.C., “Adhesion of film coatings to tablet sur-faces-A theoretical approach based on solubility pa-rameters”, Int. J. Pharm., 41, 219—222(1988).
13    Rowe, R.C., “Polar/nonpolar interactions in the granula-tion of organic substrates with polymer binding agents”, Int. J. Pharm., 56, 117—124(1989).
14    Greenhalgh, D.J., Williams, A.C., Timmins, P., York, P., “Solubility parameters as predictors of miscibility in solid dispersions”, J. Pharm. Sci., 88 (11), 1182—1190(1999).
15    Suzuki, H., Sunada, H., “Influence of water-soluble polymers on the dissolution of nifedipine solid disper-sions with combined carriers”, Chem. Pharm. Bull., 45, 1688—1693(1997).
16    Hansen, C.M., “The three dimensional solubility pa-rameter–key to paint component affinities. 1: solvent, plasticizers, polymers and resins”, J. Paint Technol., 39, 104—117(1967).
17    Kreveken, D.V., Properties of Polymers, Elsevier, Am-sterdam (1990).
18    Li, J.S., Sun, J., Zhang, D.L., “Estimating the solubility parameters of rubber ingredients basing on group con-tribution”, Rubber Eng., 42(7), 393—395(1995). (in Chinese)
19    Jenning, V., Gohla, S., “Comparison of wax and glyc-eride solid lipid nanoparticles”, Int. J. Pharm., 196,  219—222(2000).
20    Sato, K., “Crystallization behaviour of fats and lipids—A review”, Chem. Eng. Sci., 56, 2255—2265(2001).
21    Hagemann, J.W., Crystallization and Polymorphism of Fats and Fatty Acids, Marcel Dekker Inc., New York (1988).
22    Freitas, C., Müller, R.H., “Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase”, Eur. J. Pharm. Bio-pharm., 47, 125—132(1999).
23    Mühlen, A.Z., Schwarz, C., Mehnert, W., “Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism”, Eur. J. Pharm. Bio-pharm., 45, 149—155(1998).
24    Chapman, D., “The polymorphism of glycerides”, Chem. Rev., 62, 433―456(1962).
25    Freitas, C., Müller, R.H., “Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion af-ter addition of electrolyte”, J. Microencaps., 16(1), 59—71(1999).
26    Souto, E.B., Wissing, S.A., Barbosa, C.M., Müller, R.H., “Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery”, In-tern. J. Pharm., 278, 71—77(2004).
27    Yoshino, H., Kobayashi, M., Samejima, M., “The influ-ence of drugs on the physical stability of fatty supposito-ries”, Chem. Pharm. Bull., 30, 992—1001(1982).

布洛芬固体脂质微颗粒的制备及其晶体构型研究

Preparation and Crystal Modification of Ibuprofen-Loaded Solid Lipid Microparticles

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价